Foghorn therapeutics appoints michael lacascia as chief legal officer

Cambridge, mass., nov. 12, 2020 (globe newswire) -- foghorn therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of michael lacascia as its chief legal officer. an accomplished attorney, mr. lacascia joins foghorn with extensive corporate, securities, governance, and transactional expertise within the biotechnology industry.
FHTX Ratings Summary
FHTX Quant Ranking